Shield launches review after spotting flaw in 'Feraccru' study
17th Mar 2020 15:17
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics updated the market on the 'AEGIS-H2H' clinical trial on Tuesday, the data of which was primarily designed to be used in health economic analyses, pricing and reimbursement applications, as well as marketing purposes.
Read moreShield Therapeutics details year of 'material progress'
27th Jan 2020 08:09
(Sharecast News) - Drugs developer Shield Therapeutics told investors on Monday that 2019 had been a year of "material progress", with a key success being the recent Federal Drug Administration approval of its iron deficiency treatment, Feraccru/Accrufer.
Read moreShield Therapeutics narrows losses as it advances Feraccru to market
3rd Apr 2019 10:10
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics announced a decent improvement in revenue in its preliminary results on Wednesday, to £11.9m from £0.6m.
Read moreShield Therapeutics upbeat on latest Feraccru trial results
4th Mar 2019 11:26
(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced positive results from the AEGIS-H2H clinical trial on Monday, which compared 'Feraccru' (ferric maltol) - a novel oral iron replacement therapy - to 'Ferinject' (ferric carboxymaltose - FCM), the market-leading intravenously delivered iron replacement therapy.
Read moreShield Therapeutics upbeat on results of latest Feraccru study
29th Jan 2019 10:02
(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced positive results from the open-label extension phase of the AEGIS-CKD pivotal study of 'Feraccru' on Tuesday.
Read moreShield Therapeutics revenues surge following commercialisation deal
24th Jan 2019 10:02
(Sharecast News) - Shield Therapeutics saw revenues rocket in the second half of its trading year following a commercialisation agreement with European pharmaceutical specialist Norgine.
Read moreShield Therapeutics promotes Karis to chairman
22nd Jan 2019 09:56
(Sharecast News) - Commercial stage pharmaceutical outfit Shield Therapeutics elevated James Karis to the role of non-executive chairman on Tuesday.
Read moreFDA gives target date for Shield's Feraccru application
13th Dec 2018 11:57
(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced on Thursday that the US Food and Drug Administration (FDA) has confirmed that the target date for completion of the New Drug Application (NDA) review of 'Feraccru', under the terms of the Prescription Drug User Fee Act, would be 27 July 2019.
Read moreShield Therapeutics' Feraccru treatment launched in UK
5th Dec 2018 13:07
(Sharecast News) - Shield Therapeutics' treatment for iron deficiency in adults, Feraccru, was launched in the UK on Wednesday by specialist pharmaceutical company Norgine.
Read moreShield Therapeutics irons losses, agrees commercialisation deal
19th Sep 2018 08:36
(Sharecast News) - Iron deficiency treatment specialist Shield Therapeutics narrowed losses as revenues grew in the first half of that saw a series of positive developments.
Read moreShield Therapeutics sees 'encouraging' demand for oral iron product in England, Germany
6th Jan 2017 08:12
(ShareCast News) - AIM-listed pharmaceutical Shield Therapeutics saw "encouraging" demand for its oral iron product in the England and Germany. The company said is seeing "very encouraging signals of demand" after only six months since the commercial launch of Feraccru, which treats of iron deficien
Read more